The plasmepsin family as antimalarial drug targets

Aspartic Acid Proteases as Therapeutic Targets

Volumn 45, Issue , 2011, Pages 511-547

  Ruben, Adam J ^a   Kiso, Yoshiaki ^b   Freire, Ernesto ^c  

^a SANARIA INC   (United States)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Adaptive ligand; Aspartic protease inhibitor; Binding affinity; Enthalpy; Food vacuole; Hemoglobin degradation; Isothermal titration calorimetry; Plasmepsin; Plasmodium; Thermodynamic optimization

Indexed keywords

EID: 84857747026     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527630943.ch18     Document Type: Chapter

References (175)

1. WorldHealth Organization (2004)World Health Organization Fact Sheet No. 94-Malaria,World Health Organization, Geneva.
2. Gwadz, R. (2001) in Malaria in Africa: An Overview -Report from a Symposium Held at the 2001 AAAS Annual Meeting, Malaria in Africa: Emerging Prevention and Control Strategies, San Francisco, CA, February 17, 2001; San Francisco, CA.
3. Roll Back Malaria, World Health Organization, UNICEF (2005) World Malaria Report 2005, Roll Back Malaria, World Health Organization, UNICEF, p. 36.
4. Escalante, A.A.and Ayala, F.J. (1994) Phylogeny of the malarial genus Plasmodium, derived from rRNA gene sequences. Proceedings of the National Academy of Sciences of the United States of America, 91, 11373-11377.
5. Vythilingam, I., Tan, C.H., Asmad, M., Chan, S.T., Lee, K.S., and Singh, B. (2006) Natural transmission of Plasmodium knowlesi to humans by Anopheles latens in Sarawak, Malaysia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 100, 1087-1088.
6. Singh, B., Kim Sung, L., Matusop, A., Radhakrishnan, A., Shamsul, S.S., Cox-Singh, J., Thomas, A., and Conway, D.J. (2004) A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet, 363, 1017-1024.
7. Daneshvar, C., Davis, T.M., Cox-Singh, J., Rafa'ee, M.Z., Zakaria, S.K., Divis, P.C., and Singh, B. (2009) Clinical and laboratory features of human Plasmodium knowlesi infection. Clinical Infectious Diseases, 49, 852-860.
8. Gardner, M.J., Hall, N., Fung, E., White, O., Berriman, M., Hyman, R.W., Carlton, J.M., Pain, A., Nelson, K.E., Bowman, S., Paulsen, I.T., James, K., Eisen, J.A., Rutherford, K., Salzberg, S.L., Craig, A., Kyes, S., Chan, M.S., Nene, V., Shallom, S.J., Suh, B., Peterson, J., Angiuoli, S., Pertea, M., Allen, J., Selengut, J.,Haft, D., Mather, M.W., Vaidya, A.B., Martin, D.M., Fairlamb, A.H., Fraunholz, M.J., Roos, D.S., Ralph, S.A., McFadden, G.I., Cummings, L.M., Subramanian, G.M., Mungall, C., Venter, J.C., Carucci, D.J., Hoffman, S.L., Newbold, C., Davis, R.W., Fraser, C.M., and Barrell, B. (2002) Genome sequence of the human malaria parasite Plasmodium falciparum. Nature, 419, 498-511.
9. Carlton, J.M., Adams, J.H., Silva, J.C., Bidwell, S.L., Lorenzi, H., Caler, E., Crabtree, J., Angiuoli, S.V., Merino, E.F., Amedeo, P., Cheng, Q., Coulson, R.M., Crabb, B.S., Del Portillo, H.A., Essien, K., Feldblyum, T.V., Fernandez-Becerra, C., Gilson, P.R., Gueye, A.H., Guo, X., Kanga, S., Kooij, T.W., Korsinczky, M., Meyer, E.V., Nene, V., Paulsen, I., White, O., Ralph, S.A., Ren, Q., Sargeant, T.J., Salzberg, S.L., Stoeckert, C.J., Sullivan, S.A., Yamamoto, M.M., Hoffman, S.L., Wortman, J.R., Gardner, M.J., Galinski, M.R., Barnwell, J.W., and Fraser-Liggett, C.M. (2008) Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature, 455, 757-763.
10. Pain, A., Bohme, U., Berry, A.E., Mungall, K., Finn, R.D., Jackson, A.P., Mourier, T., Mistry, J., Pasini, E.M., Aslett, M.A., Balasubrammaniam, S., Borgwardt, K., Brooks, K., Carret, C., Carver, T.J., Cherevach, I., Chillingworth, T., Clark, T.G., Galinski, M.R., Hall, N., Harper, D.,Harris, D.,Hauser, H., Ivens, A., Janssen, C.S., Keane, T., Larke, N., Lapp, S., Marti, M., Moule, S., Meyer, I.M., Ormond, D., Peters, N., Sanders, M., Sanders, S., Sargeant, T.J., Simmonds, M., Smith, F., Squares, R., Thurston, S., Tivey, A.R., Walker, D., White, B., Zuiderwijk, E., Churcher, C., Quail, M.A., Cowman, A.F., Turner, C.M., Rajandream, M.A., Kocken, C.H., Thomas, A.W., Newbold, C.I., Barrell, B.G., and Berriman, M. (2008) The genome of the simian and human malaria parasite Plasmodium knowlesi. Nature, 455, 799-803.
11. Goldberg, D.E. (1993) Hemoglobin degradation in Plasmodium-infected red blood cells. Seminars in Cell Biology, 4, 355-361.
12. Ginsburg, H. (1990) Some reflections concerning host erythrocyte-malarial parasite interrelationships. Blood Cells, 16, 225-235.
13. Boss, C., Richard-Bildstein, S.,Weller, T., Fischli, W., Meyer, S., and Binkert, C. (2003) Inhibitors of the Plasmodium falciparum parasite aspartic protease plasmepsin II as potential antimalarial agents. Current Medicinal Chemistry, 10, 883-907.
14. Francis, S.E., Banerjee, R., and Goldberg, D.E. (1997) Biosynthesis and maturation of the malaria aspartic hemoglobinases plasmepsins I and II. The Journal of Biological Chemistry, 272, 14961-14968.
15. Lew, V.L., Tiffert, T., and Ginsburg, H. (2003) Excess hemoglobin digestion and the osmotic stability of Plasmodium falciparum-infected red blood cells. Blood, 101, 4189-4194.
16. Aikawa, M.,Hepler, P.K.,Huff, C.G., and Sprinz, H. (1966) The feeding mechanism of avian malarial parasites. The Journal of Cell Biology, 28, 355-373.
17. Slomianny, C. (1990) Three-dimensional reconstruction of the feeding process of the malaria parasite. Blood Cells, 16, 369-378.
18. Eggleson, K.K., Duffin, K.L., and Goldberg, D.E. (1999) Identification and characterization of falcilysin, a metallopeptidase involved in hemoglobin catabolism within the malaria parasite Plasmodium falciparum. The Journal of Biological Chemistry, 274, 32411-32417.
19. Gluzman, I.Y., Francis, S.E., Oksman, A., Smith, C.E., Duffin, K.L., and Goldberg, D.E. (1994) Order and specificity of the Plasmodium falciparum hemoglobin degradation pathway. The Journal of Clinical Investigation, 93, 1602-1608.
20. Goldberg, D.E., Slater, A.F., Beavis, R., Chait, B., Cerami, A., and Henderson, G.B. (1991) Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: a catabolic pathway initiated by a specific aspartic protease. The Journal of Experimental Medicine, 173, 961-969.
21. Sijwali, P.S., Shenai, B.R., Gut, J., Singh, A., and Rosenthal, P.J. (2001) Expression and characterization of the Plasmodium falciparum haemoglobinase falcipain-3. The Biochemical Journal, 360, 481-489.
22. Moura, P.A., Dame, J.B., and Fidock, D.A. (2009) Evaluation of the role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors. Antimicrobial Agents and Chemotherapy, 53, 4968-4978.
23. Luker, K.E., Francis, S.E., Gluzman, I.Y., and Goldberg, D.E. (1996) Kinetic analysis of plasmepsins I and II aspartic proteases of the Plasmodium falciparum digestive vacuole. Molecular and Biochemical Parasitology, 79, 71-78.
24. Francis, S.E., Gluzman, I.Y., Oksman, A., Banerjee, D., and Goldberg, D.E. (1996) Characterization of native falcipain: an enzyme involved in Plasmodium falciparum hemoglobin degradation. Molecular and Biochemical Parasitology, 83, 189-200.
25. Banerjee, R., Liu, J., Beatty, W., Pelosof, L., Klemba, M., and Goldberg, D.E. (2002) Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proceedings of the National Academy of Sciences of the United States of America, 99, 990-995.
26. Klemba, M., Gluzman, I., and Goldberg, D.E. (2004) A Plasmodium falciparum dipeptidyl aminopeptidase I participates in vacuolar hemoglobin degradation. The Journal of Biological Chemistry, 279, 43000-43007.
27. Kolakovich, K.A., Gluzman, I.Y., Duffin, K.L., and Goldberg, D.E. (1997) Generation of hemoglobin peptides in the acidic digestive vacuole of Plasmodium falciparum implicates peptide transport in amino acid production. Molecular and Biochemical Parasitology, 87, 123-135.
28. Olson, J.E., Lee, G.K., Semenov, A., and Rosenthal, P.J. (1999) Antimalarial effects in mice of orally administered peptidyl cysteine protease inhibitors. Bioorganic & Medicinal Chemistry, 7, 633-638.
29. Rosenthal, P.J. (1995) Plasmodium falciparum: effects of proteinase inhibitors on globin hydrolysis by cultured malaria parasites. Experimental Parasitology, 80, 272-281.
30. Le Bonniec, S., Deregnaucourt, C., Redeker, V., Banerjee, R., Grellier, P., Goldberg, D.E., and Schrevel, J. (1999) Plasmepsin II, an acidic hemoglobinase from the Plasmodium falciparum food vacuole, is active at neutralpHon the host erythrocyte membrane skeleton. The Journal of Biological Chemistry, 274, 14218-14223.
31. Blackman, M.J. (2008)Malarial proteases and host cell egress: an "emerging" cascade. Cellular Microbiology, 10, 1925-1934.
32. Tang, J.and Wong, R.N. (1987) Evolution in the structure and function of aspartic proteases. Journal of Cellular Biochemistry, 33, 53-63.
33. Francis, S.E., Gluzman, I.Y., Oksman, A., Knickerbocker, A., Mueller, R., Bryant, M.L., Sherman, D.R., Russell, D.G., and Goldberg, D.E. (1994) Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase. The EMBO Journal, 13, 306-317.
34. Banerjee, R., Francis, S.E., and Goldberg, D.E. (2003) Food vacuole plasmepsins are processed at a conserved site by an acidic convertase activity in Plasmodium falciparum. Molecular and Biochemical Parasitology, 129, 157-165.
35. Drew, M.E., Banerjee, R., Uffman, E.W., Gilbertson, S., Rosenthal, P.J., and Goldberg, D.E. (2008) Plasmodium food vacuole plasmepsins are activated by falcipains. The Journal of Biological Chemistry, 283, 12870-12876.
36. Coombs, G.H., Goldberg, D.E., Klemba, M., Berry, C., Kay, J., and Mottram, J.C. (2001) Aspartic proteases of Plasmodium falciparumand other parasitic protozoa as drug targets. Trends in Parasitology, 17, 532-537.
37. Klemba, M.and Goldberg, D.E. (2005) Characterization of plasmepsin V, a membrane-bound aspartic protease homolog in the endoplasmic reticulum of Plasmodium falciparum. Molecular and Biochemical Parasitology, 143, 183-191.
38. Vassar, R., Bennett, B.D., Babu-Khan, S., Kahn, S., Mendiaz, E.A., Denis, P., Teplow, D.B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jarosinski, M.A., Biere, A.L., Curran, E., Burgess, T., Louis, J.C., Collins, F., Treanor, J., Rogers, G., and Citron, M. (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science, 286, 735-741.
39. Jean, L., Grosclaude, J., Labbe, M., Tomley, F., and Pery, P. (2000) Differential localisation of an Eimeria tenella aspartyl proteinase during the infection process. International Journal for Parasitology, 30, 1099-1107.
40. Laurent, F., Bourdieu, C., Kaga, M., Chilmonczyk, S., Zgrzebski, G., Yvore, P., and Pery, P. (1993) Cloning and characterization of an Eimeria acervulina sporozoite gene homologous to aspartyl proteinases. Molecular and Biochemical Parasitology, 62, 303-312.
41. Bonilla, J.A., Moura, P.A., Bonilla, T.D., Yowell, C.A., Fidock, D.A., and Dame, J.B. (2007) Effects on growth, hemoglobin metabolism and paralogous gene expression resulting from disruption of genes encoding the digestive vacuole plasmepsins of Plasmodium falciparum. International Journal for Parasitology, 37, 317-327.
42. Liu, J., Gluzman, I.Y., Drew, M.E., and Goldberg, D.E. (2005) The role of Plasmodium falciparum food vacuole plasmepsins. The Journal of Biological Chemistry, 280, 1432-1437.
43. Omara-Opyene, A.L., Moura, P.A., Sulsona, C.R., Bonilla, J.A., Yowell, C.A., Fujioka, H., Fidock, D.A., and Dame, J.B. (2004) Genetic disruption of the Plasmodium falciparum digestive vacuole plasmepsins demonstrates their functional redundancy. The Journal of Biological Chemistry, 279, 54088-54096.
44. Fischer, E. (1894) Einfluss der Konfiguration auf die Wirkung der Enzyme. Berichte Der Deutschen Chemischen Gesellschaft, 27, 2985-2993.
45. Nezami, A., Kimura, T., Hidaka, K., Kiso, A., Liu, J., Kiso, Y., Goldberg, D.E., and Freire, E. (2003) High-affinity inhibition of a family of Plasmodium falciparum proteases by a designed adaptive inhibitor. Biochemistry, 42, 8459-8464.
46. Freire, E. (2002) Designing drugs against heterogeneous targets. Nature Biotechnology, 20, 15-16.
47. Velazquez-Campoy, A.and Freire, E. (2001) Incorporating target heterogeneity in drug design. Journal of Cellular Biochemistry, 37 (Suppl.), 82-88.
48. Ohtaka, H.and Freire, E. (2005) Adaptive inhibitors of the HIV-1 protease. Progress in Biophysics and Molecular Biology, 88, 193-208.
49. Liu, J., Istvan, E.S., Gluzman, I.Y., Gross, J., and Goldberg, D.E. (2006) Plasmodium falciparum ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems. Proceedings of the National Academy of Sciences of the United States of America, 103, 8840-8845.
50. Dame, J.B. (1996) Additional plasmepsins, Handbook of Proteolytic Enzymes (eds A. Barrett, N. Rawlings, and F. Woessner) Academic Press, London, pp. 864-864.
51. Humphreys, M.J., Moon, R.P., Klinder, A., Fowler, S.D., Rupp, K., Bur, D., Ridley, R.G., and Berry, C. (1999) The aspartic proteinase from the rodent parasite Plasmodium berghei as a potential model for plasmepsins from the human malaria parasite, Plasmodium falciparum. FEBS Letters, 463, 43-48.
52. Martins, T.M., Novo, C., do Rosario, V.E., and Domingos, A. (2003) Aspartic proteases from Plasmodium chabaudi: a rodent model for human malaria. Acta Tropica, 89, 1-12.
53. Dame, J.B., Yowell, C.A., Omara-Opyene, L., Carlton, J.M., Cooper, R.A., and Li, T. (2003) Plasmepsin 4, the food vacuole aspartic proteinase found in all Plasmodium spp. infecting man. Molecular and Biochemical Parasitology, 130, 1-12.
54. Hill, J., Tyas, L., Phylip, L.H., Kay, J., Dunn, B.M., and Berry, C. (1994) High level expression and characterisation of plasmepsin II, an aspartic proteinase from Plasmodium falciparum. FEBS Letters, 352, 155-158.
55. Gulnik, S.V., Afonina, E.I., Gustchina, E., Yu, B., Silva, A.M., Kim, Y., and Erickson, J.W. (2002) Utility of (His) 6. tag for purification and refolding of proplasmepsin-2 and mutants with altered activation properties. Protein Expression and Purification, 24, 412-419.
56. Moon, R.P., Tyas, L., Certa, U., Rupp, K., Bur, D., Jacquet, C., Matile, H., Loetscher, H.,Grueninger-Leitch, F., Kay, J., Dunn, B.M., Berry, C., and Ridley, R.G. (1997) Expression and characterisation of plasmepsin I from Plasmodium falciparum. European Journal of Biochemistry, 244, 552-560.
57. Scarborough, P.E.and Dunn, B.M. (1994) Redesign of the substrate specificity of human cathepsin D: the dominant role of position 287 in the S2 subsite. Protein Engineering, 7, 495-502.
58. Tyas, L., Gluzman, I., Moon, R.P., Rupp, K., Westling, J., Ridley, R.G., Kay, J., Goldberg, D.E., and Berry, C. (1999) Naturally-occurring and recombinant forms of the aspartic proteinases plasmepsins I and II from the human malaria parasite Plasmodium falciparum. FEBS Letters, 454, 210-214.
59. Xiao, H., Tanaka, T., Ogawa, M., and Yada, R.Y. (2007) Expression and enzymatic characterization of the soluble recombinant plasmepsin I from Plasmodium falciparum. Protein Engineering, Design & Selection, 20, 625-633.
60. Liu, P., Marzahn, M.R., Robbins, A.H., Gutierrez-de-Teran, H., Rodriguez, D., McClung, S.H., Stevens, S.M., Jr., Yowell, C.A., Dame, J.B., McKenna, R., and Dunn, B.M. (2009) Recombinant plasmepsin 1 from the human malaria parasite Plasmodium falciparum: enzymatic characterization, active site inhibitor design, and structural analysis. Biochemistry, 48, 4086-4099.
61. Beyer, B.M.and Dunn, B.M. (1996) Self-activation of recombinant human lysosomal procathepsin D at a newly engineered cleavage junction, short? pseudocathepsin D. The Journal of Biological Chemistry, 271, 15590-15596.
62. Siripurkpong, P., Yuvaniyama, J., Wilairat, P., and Goldberg, D.E. (2002) Active site contribution to specificity of the aspartic proteases plasmepsins I and II. The Journal of Biological Chemistry, 277, 41009-41013.
63. Wyatt, D.M.and Berry, C. (2002) Activity and inhibition of plasmepsin IV, a new aspartic proteinase from the malaria parasite, Plasmodium falciparum. FEBS Letters, 513, 159-162.
64. Li, T., Yowell, C.A., Beyer, B.B., Hung, S.H., Westling, J., Lam, M.T., Dunn, B.M., and Dame, J.B. (2004) Recombinant expression and enzymatic subsite characterization of plasmepsin 4 from the four Plasmodium species infecting man. Molecular and Biochemical Parasitology, 135, 101-109.
65. Berry, C., Humphreys, M.J.,Matharu, P., Granger, R., Horrocks, P., Moon, R.P., Certa, U., Ridley, R.G., Bur, D., and Kay, J. (1999) A distinct member of the aspartic proteinase gene family from the human malaria parasite Plasmodium falciparum. FEBS Letters, 447, 149-154.
66. Xiao, H., Sinkovits, A.F., Bryksa, B.C., Ogawa, M., and Yada, R.Y. (2006) Recombinant expression and partial characterization of an active soluble histo-aspartic protease from Plasmodium falciparum. Protein Expression and Purification, 49, 88-94.
67. Polgar, L. (1987) The mechanism of action of aspartic proteases involves push-pull? catalysis. FEBS Letters, 219, 1-4.
68. Dash, C., Kulkarni, A., Dunn, B., and Rao, M. (2003) Aspartic peptidase inhibitors: implications in drug development. Critical Reviews in Biochemistry and Molecular Biology, 38, 89-119.
69. Andreeva, N., Bogdanovich, P., Kashparov, I., Popov, M., and Stengach, M. (2004) Is histoaspartic protease a serine protease with a pepsin-like fold? Proteins, 55, 705-710.
70. Popov, M.E., Sten?gach, M.A., and Andreeva, N.S. (2008) Modeling of substrate and inhibitory complexes of histidine-aspartic protease. Bioorganicheskaia Khimiia, 34, 422-429.
71. Bjelic, S.and Aqvist, J. (2004) Computational prediction of structure, substrate binding mode, mechanism, and rate for a malaria protease with a novel type of active site. Biochemistry, 43, 14521-14528.
72. Krogstad, D.J., Schlesinger, P.H., and Gluzman, I.Y. (1985) Antimalarials increase vesicle pH in Plasmodium falciparum. The Journal ofCell Biology, 101, 2302-2309.
73. Yayon, A., Cabantchik, Z.I., and Ginsburg, H. (1984) Identification of the acidic compartment of Plasmodium falciparum-infected human erythrocytes as the target of the antimalarial drug chloroquine. The EMBO Journal, 3, 2695-2700.
74. Klonis, N., Tan, O., Jackson, K., Goldberg, D., Klemba, M., and Tilley, L. (2007) Evaluation of pH during cytostomal endocytosis and vacuolar catabolism of hemoglobin in Plasmodium falciparum. The Biochemical Journal, 407, 343-354
75. Westling, J., Cipullo, P.,Hung, S.H., Saft, H., Dame, J.B., and Dunn, B.M. (1999) Active site specificity of plasmepsin II. Protein Science: A Publication of the Protein Society, 8, 2001-2009.
76. Jupp, R.A., Dunn, B.M., Jacobs, J.W., Vlasuk, G., Arcuri, K.E., Veber, D.F., Perlow, D.S., Payne, L.S., Boger, J., de Laszlo, S. et al. (1990) The selectivity of statine-based inhibitors against various human aspartic proteinases. The Biochemical Journal, 265, 871-878.
77. Dunn, B.M.and Hung, S. (2000) The two sides of enzyme-substrate specificity: lessons from the aspartic proteinases. Biochimica et Biophysica Acta, 1477, 231-240.
78. Schechter, I.and Berger, A. (1967) On the size of the active site in proteases. I. Papain. Biochemical and Biophysical Research Communications, 27, 157-162.
79. Beyer, B.B., Johnson, J.V., Chung, A.Y., Li, T., Madabushi, A., Agbandje-McKenna, M., McKenna, R., Dame, J.B., and Dunn, B.M. (2005) Active-site specificity of digestive aspartic peptidases from the four species of Plasmodium that infect humans using chromogenic combinatorial peptide libraries. Biochemistry, 44, 1768-1779.
80. Eder, J., Hommel, U., Cumin, F., Martoglio, B., and Gerhartz, B. (2007) Aspartic proteases in drug discovery. Current Pharmaceutical Design, 13, 271-285.
81. Westling, J., Yowell, C.A., Majer, P., Erickson, J.W., Dame, J.B., and Dunn, B.M. (1997) Plasmodium falciparum, P. vivax, and P. malariae: a comparison of the active site properties of plasmepsins cloned and expressed from three different species of the malaria parasite. Experimental Parasitology, 87, 185-193.
82. White, N.J. (1999) Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia, 41, 301-308.
83. Powers, J.C., Harley, A.D., and Myers, D.V. (1977) Subsite specificity of porcine pepsin. Advances in Experimental Medicine and Biology, 95, 141-157.
84. Scarborough, P.E., Guruprasad, K., Topham, C., Richo, G.R., Conner, G.E., Blundell, T.L., and Dunn, B.M. (1993) Exploration of subsite binding specificity of human cathepsin D through kinetics and rule-based molecular modeling. Protein Science: A Publication of the Protein Society, 2 (2), 264-276.
85. Istvan, E.S.and Goldberg, D.E. (2005) Distal substrate interactions enhance plasmepsin activity. The Journal of Biological Chemistry, 280, 6890-6896.
86. Silva, A.M., Lee, A.Y., Gulnik, S.V.,Maier, P., Collins, J., Bhat, T.N., Collins, P.J., Cachau, R.E., Luker, K.E., Gluzman, I.Y., Francis, S.E., Oksman, A., Goldberg, D.E., and Erickson, J.W. (1996) Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum. Proceedings of the National Academy of Sciences of the United States of America, 93, 10034-10039.
87. Umezawa, H., Aoyagi, T., Morishima, H., Matsuzaki, M., and Hamada, M. (1970) Pepstatin, a new pepsin inhibitor produced by Actinomycetes. The Journal of Antibiotics, 23, 259-262.
88. Asojo, O.A.,Gulnik, S.V., Afonina, E., Yu, B., Ellman, J.A., Haque, T.S., and Silva, A.M. (2003) Novel uncomplexed and complexed structures of plasmepsin II, an aspartic protease from Plasmodium falciparum. Journal of Molecular Biology, 327, 173-181.
89. Bernstein, N.K., Cherney, M.M., Yowell, C.A., Dame, J.B., and James, M.N. (2003) Structural insights into the activation of P. vivax plasmepsin. Journal of Molecular Biology, 329, 505-524.
90. Davies, D.R. (1990) The structure and function of the aspartic proteinases. Annual Review of Biophysics and Biophysical Chemistry, 19, 189-215.
91. Asojo, O.A., Afonina, E.,Gulnik, S.V., Yu, B., Erickson, J.W., Randad, R.,Medjahed, D., and Silva, A.M. (2002) Structures of Ser205 mutant plasmepsin II from Plasmodium falciparum at 1.8 A in complex with the inhibitors rs367 and rs370. Acta Crystallographica. Section D: Biological Crystallography, 58, 2001-2008.
92. Gerstein, M., Lesk, A.M., and Chothia, C. (1994) Structural mechanisms for domain movements in proteins. Biochemistry, 33, 6739-6749.
93. Bernstein, N.K., Cherney, M.M., Loetscher, H., Ridley, R.G., and James, M.N. (1999) Crystal structure of the novel aspartic proteinase zymogen proplasmepsin II from Plasmodium falciparum. Nature Structural Biology, 6, 32-37.
94. Madabushi, A., Chakraborty, S., Fisher, S.Z., Clemente, J.C., Yowell, C., Agbandje-McKenna, M., Dame, J.B., Dunn, B.M., and McKenna, R. (2005) Crystallization and preliminary X-ray analysis of the aspartic protease plasmepsin 4 from the malarial parasite Plasmodium malariae. Acta Crystallographica. Section F: Structural Biology and Crystallization Communications, 61, 228-231.
95. Clemente, J.C., Govindasamy, L., Madabushi, A., Fisher, S.Z., Moose, R.E., Yowell, C.A., Hidaka, K., Kimura, T., Hayashi, Y., Kiso, Y., Agbandje-McKenna, M., Dame, J.B., Dunn, B.M., and McKenna, R. (2006) Structure of the aspartic protease plasmepsin 4 from the malarial parasite Plasmodium malariae bound to an allophenylnorstatine-based inhibitor. Acta Crystallographica. Section D: Biological Crystallography, 62, 246-252.
96. Prade, L., Jones, A.F., Boss, C., Richard-Bildstein, S., Meyer, S., Binkert, C., and Bur, D. (2005) X-ray structure of plasmepsin II complexed with a potent achiral inhibitor. The Journal of Biological Chemistry, 280, 23837-23843.
97. Johansson, P.O., Lindberg, J., Blackman, M.J., Kvarnstrom, I., Vrang, L., Hamelink, E., Hallberg, A., Rosenquist, A., and Samuelsson, B. (2005) Design and synthesis of potent inhibitors of plasmepsin I and II: X-ray crystal structure of inhibitor in complex with plasmepsin II. Journal of Medicinal Chemistry, 48, 4400-4409.
98. Robbins, A.H., Dunn, B.M., Agbandje-McKenna, M., and McKenna, R. (2009) Crystallographic evidence for noncoplanar catalytic aspartic acids in plasmepsin II resides in the Protein Data Bank. Acta Crystallographica. Section D: Biological Crystallography, 65, 294-296.
99. Goldberg, D.E.and Istvan, E.S. (2004) in New Antimalarial Strategies from Scrutinizing Plasmepsins, Eighteenth Symposium of The Protein Society, San Diego, CA, 2004 (ed. M. Hermodson), Cold Spring Harbor Laboratory Press, San Diego, CA, pp. 61-62.
100. Liu, J., Istvan, E.S., and Goldberg, D.E. (2006) Hemoglobin-degrading plasmepsin II is active as a monomer. The Journal of Biological Chemistry, 281, 38682-38688.
101. Abdel-Rahman, H.M., Kimura, T., Hidaka, K., Kiso, A., Nezami, A., Freire, E.,Hayashi, Y., and Kiso, Y. (2004) Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases. Biological Chemistry, 385, 1035-1039.
102. Andrews, K.T., Fairlie, D.P.,Madala, P.K., Ray, J., Wyatt, D.M., Hilton, P.M., Melville, L.A., Beattie, L., Gardiner, D.L., Reid, R.C., Stoermer, M.J., Skinner-Adams, T., Berry, C., and McCarthy, J.S. (2006) Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrobial Agents and Chemotherapy, 50, 639-648.
103. Bhattacharjee, A.K., Hartell, M.G., Nichols, D.A., Hicks, R.P., Stanton, B., van Hamont, J.E., and Milhous, W.K. (2004) Structure-activity relationship study of antimalarial indolo [2,1-b] quinazoline-6,12-diones (tryptanthrins). Three dimensional pharmacophore modeling and identification of new antimalarial candidates. European Journal of Medicinal Chemistry, 39, 59-67.
104. Boss, C., Corminboeuf, O., Grisostomi, C., Meyer, S., Jones, A.F., Prade, L., Binkert, C., Fischli, W., Weller, T., and Bur, D. (2006) Achiral, cheap, and potent inhibitors of plasmepsins I, II, and IV. ChemMedChem, 1, 1341-1345.
105. Carcache, D.A., Hortner, S.R., Bertogg, A., Binkert, C., Bur, D., Marki, H.P., Dorn, A., and Diederich, F. (2002) De novo design, synthesis, and in vitro evaluation of a new class of nonpeptidic inhibitors of the malarial enzyme plasmepsin II. Chembiochem: A European Journal of Chemical Biology, 3, 1137-1141.
106. Carroll, C.D., Johnson, T.O., Tao, S., Lauri, G., Orlowski, M., Gluzman, I.Y., Goldberg, D.E., and Dolle, R.E. (1998) Evaluation of a structure-based statine cyclic diamino amide encoded combinatorial library against plasmepsin II and cathepsin D. Bioorganic &Medicinal Chemistry Letters, 8, 3203-3206.
107. Carroll, C.D., Patel, H., Johnson, T.O., Guo, T., Orlowski, M., He, Z.M., Cavallaro, C.L., Guo, J., Oksman, A., Gluzman, I.Y., Connelly, J., Chelsky, D., Goldberg, D.E., and Dolle, R.E. (1998) Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library. Bioorganic & Medicinal Chemistry Letters, 8, 2315-2320.
108. Corminboeuf, O., Dunet, G., Hafsi, M., Grimont, J., Grisostomi, C., Meyer, S., Binkert, C., Bur, D., Jones, A., Prade, L., Brun, R., and Boss, C. (2006) Inhibitors of plasmepsin II-potential antimalarial agents. Bioorganic & Medicinal Chemistry Letters, 16 (24), 6194-6199.
109. Dahlgren, A., Kvarnstrom, I., Vrang, L., Hamelink, E., Hallberg, A., Rosenquist, A., and Samuelsson, B. (2003) New inhibitors of the malaria aspartyl proteases plasmepsin I and II. Bioorganic & Medicinal Chemistry, 11, 3423-3437.
110. Dahlgren, A., Kvarnstrom, I., Vrang, L., Hamelink, E., Hallberg, A., Rosenquist, A., and Samuelsson, B. (2003) Solidphase library synthesis of reversed-statine type inhibitors of the malarial aspartyl proteases plasmepsin I and II. Bioorganic & Medicinal Chemistry, 11, 827-841.
111. Dell'Agli, M., Parapini, S., Basilico, N., Verotta, L., Taramelli, D., Berry, C., and Bosisio, E. (2003) In vitro studies on the mechanism of action of two compounds with antiplasmodial activity: ellagic acid and 3,4,5-trimethoxyphenyl(60-O-aalloyl)-beta-d-glucopyranoside. Planta Medica, 69, 162-164.
112. Dell'Agli, M., Parapini, S., Galli, G., Vaiana, N., Taramelli, D., Sparatore, A., Liu, P., Dunn, B.M., Bosisio, E., and Romeo, S. (2006) High antiplasmodial activity of novel plasmepsins I and II inhibitors. Journal ofMedicinal Chemistry, 49, 7440-7449.
113. Ersmark, K., Feierberg, I., Bjelic, S., Hamelink, E., Hackett, F., Blackman, M.J., Hulten, J., Samuelsson, B., Aqvist, J., and Hallberg, A. (2004) Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity. Journal of Medicinal Chemistry, 47, 110-122.
114. Ersmark, K., Feierberg, I., Bjelic, S., Hulten, J., Samuelsson, B., Aqvist, J., and Hallberg, A. (2003) C2-symmetric inhibitors of Plasmodium falciparum plasmepsin II: synthesis and theoretical predictions. Bioorganic & Medicinal Chemistry, 11, 3723-3733.
115. Ersmark, K., Nervall, M., Gutierrez-de-Teran, H., Hamelink, E., Janka, L.K., Clemente, J.C., Dunn, B.M., Gogoll, A., Samuelsson, B., Qvist, J., and Hallberg, A. (2006) Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV. Bioorganic & Medicinal Chemistry, 14, 2197-2208.
116. Ersmark, K., Nervall, M., Hamelink, E., Janka, L.K., Clemente, J.C., Dunn, B.M., Blackman, M.J., Samuelsson, B., Aqvist, J., and Hallberg, A. (2005) Synthesis of malarial plasmepsin inhibitors and prediction of binding modes by molecular dynamics simulations. Journal of Medicinal Chemistry, 48, 6090-6106.
117. Guo, T.and Hobbs, D.W. (2002) Preparation of encoded combinatorial libraries for drug discovery. Methods in Molecular Biology (Clifton, NJ), 201, 23-39.
118. Haque, T.S., Skillman, A.G., Lee, C.E., Habashita, H., Gluzman, I.Y., Ewing, T.J., Goldberg, D.E., Kuntz, I.D., and Ellman, J.A. (1999) Potent, low-molecular-weight non-peptide inhibitors of malarial aspartyl protease plasmepsin II. Journal of Medicinal Chemistry, 42, 1428-1440.
119. Hidaka, K., Kimura, T., Tsuchiya, Y., Kamiya, M., Ruben, A.J., Freire, E., Hayashi, Y., and Kiso, Y. (2007) Additional interaction of allophenylnorstatinecontaining tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorganic & Medicinal Chemistry Letters, 17, 3048-3052.
120. Hu, J.F., Schetz, J.A.,Kelly, M.,Peng, J.N., Ang, K.K., Flotow, H., Leong, C.Y., Ng, S.B., Buss, A.D., Wilkins, S.P., and Hamann, M.T. (2002) New antiinfective and human 5-HT2 receptor binding natural and semisynthetic compounds from the Jamaican sponge Smenospongia aurea. Journal of Natural Products, 65, 476-480.
121. Jiang, S., Prigge, S.T., Wei, L., Gao, Y., Hudson, T.H., Gerena, L., Dame, J.B., and Kyle, D.E. (2001) New class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins. Antimicrobial Agents and Chemotherapy, 45, 2577-2584.
122. Johansson, P.O., Chen, Y., Belfrage, A.K., Blackman, M.J., Kvarnstrom, I., Jansson, K., Vrang, L., Hamelink, E., Hallberg, A., Rosenquist, A., and Samuelsson, B. (2004) Design and synthesis of potent inhibitors of the malaria aspartyl proteases plasmepsin I and II. Use of solid-phase synthesis to explore novel statine motifs. Journal of Medicinal Chemistry, 47, 3353-3366.
123. Kiso, A.,Hidaka, K., Kimura, T.,Hayashi, Y., Nezami, A., Freire, E., and Kiso, Y. (2004) Search for substrate-based inhibitors fitting the S20 space of malarial aspartic protease plasmepsin II. Journal of Peptide Science, 10, 641-647.
124. Moon, R.P., Bur, D., Loetscher, H., D'Arcy, A., Tyas, L., Oefner, C., Grueninger-Leitch, F., Mona, D., Rupp, K., Dorn, A., Matile, H., Certa, U., Berry, C., Kay, J., and Ridley, R.G. (1998) Studies on plasmepsins I and II from the malarial parasite Plasmodium falciparum and their exploitation as drug targets. Advances in Experimental Medicine and Biology, 436, 397-406.
125. Nezami, A.and Freire, E. (2002) The integration of genomic and structural information in the development of high affinity plasmepsin inhibitors. International Journal for Parasitology, 32, 1669-1676.
126. Nezami, A., Luque, I., Kimura,T., Kiso,Y., and Freire, E. (2002) Identification and characterization of allophenylnorstatinebased inhibitors of plasmepsin II, an antimalarial target. Biochemistry, 41, 2273-2280.
127. Noteberg, D., Hamelink, E., Hulten, J., Wahlgren, M., Vrang, L., Samuelsson, B., and Hallberg, A. (2003) Design and synthesis of plasmepsin I and plasmepsin II inhibitors with activity in Plasmodium falciparum-infected cultured human erythrocytes. Journal of Medicinal Chemistry, 46, 734-746.
128. Noteberg, D., Schaal, W., Hamelink, E., Vrang, L., and Larhed, M. (2003) Highspeed optimization of inhibitors of the malarial proteases plasmepsin I and II. Journal of Combinatorial Chemistry, 5, 456-464.
129. Oscarsson, K., Oscarson, S., Vrang, L., Hamelink, E., Hallberg, A., and Samuelsson, B. (2003) New potent C2-symmetric malaria plasmepsin I and II inhibitors. Bioorganic & Medicinal Chemistry, 11, 1235-1246.
130. Ovenden, S.P., Cao, S., Leong, C., Flotow, H., Gupta, M.P., Buss, A.D., and Butler, M.S. (2002) Spermine alkaloids from Albizia adinocephala with activity against Plasmodium falciparum plasmepsin II. Phytochemistry, 60, 175-177.
131. Parikh, S., Liu, J., Sijwali, P., Gut, J., Goldberg, D.E., and Rosenthal, P.J. (2006) Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin. Antimicrobial Agents and Chemotherapy, 50, 2207-2209.
132. Pranav Kumar, S.K.and Kulkarni, V.M. (2001) Molecular dynamics simulations of the three dimensional model of plasmepsin II-peptidic inhibitor complexes. Drug Design and Discovery, 17, 293-313.
133. Romeo, S., Dell'Agli, M., Parapini, S., Rizzi, L., Galli, G., Mondani, M., Sparatore, A., Taramelli, D., and Bosisio, E. (2004) Plasmepsin II inhibition and antiplasmodial activity of primaquine-statine double-drugs?. Bioorganic & Medicinal Chemistry Letters, 14, 2931-2934.
134. Ruben, A.J., Kiso, Y., and Freire, E. (2006) Overcoming roadblocks in lead optimization: a thermodynamic perspective. Chemical Biology and Drug Design, 67, 2-4.
135. Salas, E., Ramirez, A., Otero-Bilbao, A., Vazquez, R., Reyes, O., Mendiola, J., Duarte, C.A., Otero-Gonzalez, A., Gutierrez, O.A., and Chavez, M.A. (2004) A heterogeneous enzymatic assay for quantification of plasmepsin II activity and the evaluation of its inhibitors. Journal of Pharmaceutical and Biomedical Analysis, 34, 833-840.
136. Savarino, A., Cauda, R., and Cassone, A. (2005) Aspartic proteases of Plasmodium falciparumas the target of HIV-1 protease inhibitors. The Journal of Infectious Diseases, 191, 1381-1382 author reply 1382-1383.
137. Semenov, A., Olson, J.E., and Rosenthal, P.J. (1998) Antimalarial synergy of cysteine and aspartic protease inhibitors. Antimicrobial Agents and Chemotherapy, 42, 2254-2258.
138. Sharma, A., Eapen, A., and Subbarao, S.K. (2004) Parasite killing in Plasmodium vivax malaria by nitric oxide: implication of aspartic protease inhibition. Journal of Biochemistry, 136, 329-334.
139. Sriwilaijaroen, N., Liu, M., Go, M.L., and Wilairat, P. (2006) Plasmepsin II inhibitory activity of alkoxylated and hydroxylated chalcones. The Southeast Asian Journal of Tropical Medicine and Public Health, 37, 607-612.
140. Weik, S., Luksch, T., Evers, A., Bottcher, J., Sotriffer, C.A., Hasilik, A., Loffler, H.G., Klebe, G., and Rademann, J. (2006) The potential of P1 site alterations in peptidomimetic protease inhibitors as suggested by virtual screening and explored by the use of C-C-coupling reagents. ChemMedChem, 1, 445-457.
141. Wyatt, D.M.and Berry, C. (2005) Antimalarial effects of HIV proteinase inhibitors: common compounds but structurally distinct enzymes. The Journal of Infectious Diseases, 192, 705-706.
142. Gopi, H.N., Ravindra, G., Pal, P.P., Pattanaik, P., Balaram, H., and Balaram, P. (2003) Proteolytic stability of betapeptide bonds probed using quenched fluorescent substrates incorporating a hemoglobin cleavage site. FEBS Letters, 535, 175-178.
143. Parikh, S., Gut, J., Istvan, E., Goldberg, D.E., Havlir, D.V., and Rosenthal, P.J. (2005) Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrobial Agents and Chemotherapy, 49, 2983-2985.
144. Kesavulu, M.M., Prakasha Gowda, A.S., Ramya, T.N., Surolia, N., and Suguna, K. (2005) Plasmepsin inhibitors: design, synthesis, inhibitory studies and crystal structure analysis. The Journal of Peptide Research, 66, 211-219.
145. Bjelic, S., Nervall, M., Gutierrez-de-Teran, H., Ersmark, K., Hallberg, A., and Aqvist, J. (2007) Computational inhibitor design against malaria plasmepsins. Cellular and Molecular Life Sciences, 64 2285-2305
146. Azim, M.K., Ahmed,W., Khan, I.A., Rao, N.A., and Khan, K.M. (2008) Identification of acridinyl hydrazides as potent aspartic protease inhibitors. Bioorganic & Medicinal Chemistry Letters, 18, 3011-3015.
147. Blum, A., Bottcher, J., Sammet, B., Luksch, T., Heine, A., Klebe, G., and Diederich, W.E. (2008) Achiral oligoamines as versatile tool for the development of aspartic protease inhibitors. Bioorganic & Medicinal Chemistry, 16, 8574-8586.
148. Cunico,W., Gomes, C.R., Facchinetti, V., Moreth, M., Penido, C.,Henriques, M.G., Varotti, F.P., Krettli, L.G., Krettli, A.U., da Silva, F.S., Caffarena, E.R., and de Magalhaes, C.S. (2009) Synthesis, antimalarial evaluation and molecular modeling studies of hydroxyethylpiperazines, potential aspartyl protease inhibitors, part 2. European Journal of Medicinal Chemistry, 44, 3816-3820.
149. Degliesposti, G., Kasam, V., Da Costa, A., Kang, H.K., Kim, N., Kim, D.W., Breton, V., Kim, D., and Rastelli, G. (2009) Design and discovery of plasmepsin II inhibitors using an automated workflow on largescale grids. ChemMedChem, 4, 1164-1173.
150. Dell?Agli, M., Galli, G.V., Corbett, Y., Taramelli, D., Lucantoni, L., Habluetzel, A., Maschi, O., Caruso, D., Giavarini, F., Romeo, S., Bhattacharya, D., and Bosisio, E. (2009) Antiplasmodial activity of Punica granatum L. fruit rind. Journal of Ethology, 125, 279-285.
151. Dell?Agli, M., Galli, G.V., Parapini, S., Basilico, N., Taramelli, D., Said, A., Rashed, K., and Bosisio, E. (2008) Antiplasmodial activity of Ailanthus excelsa. Fitoterapia, 79, 112-116.
152. Fah, C., Hardegger, L.A., Baitsch, L., Schweizer, W.B., Meyer, S., Bur, D., and Diederich, F. (2009) New organofluorine building blocks: inhibition of the malarial aspartic proteases plasmepsin II and IV by alicyclic alpha,alpha-difluoroketone hydrates. Organic and Biomolecular Chemistry, 7, 3947-3957.
153. Friedman, R.and Caflisch, A. (2009) Discovery of plasmepsin inhibitors by fragment-based docking and consensus scoring. ChemMedChem, 4, 1317-1326.
154. Hidaka, K., Kimura, T., Ruben, A.J., Uemura, T., Kamiya, M., Kiso, A., Okamoto, T., Tsuchiya, Y., Hayashi, Y., Freire, E., and Kiso, Y. (2008) Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isosterebased dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorganic & Medicinal Chemistry, 16, 10049-10060.
155. Janka, L., Clemente, J., Vaiana, N., Sparatore, A., Romeo, S., and Dunn, B.M. (2008) Targeting the plasmepsin 4 orthologs of Plasmodium sp. with double drug? inhibitors. Protein and Peptide Letters, 15, 868-873.
156. Kasam, V., Salzemann, J., Botha, M., Dacosta, A., Degliesposti, G., Isea, R., Kim, D., Maass, A., Kenyon, C., Rastelli, G., Hofmann-Apitius, M., and Breton, V. (2009) WISDOM-II: screening against multiple targets implicated in malaria using computational grid infrastructures. Malaria Journal, 8, 88.
157. Luksch, T., Chan, N.S., Brass, S., Sotriffer, C.A., Klebe, G., and Diederich, W.E. (2008) Computer-aided design and synthesis of nonpeptidic plasmepsin II and IV inhibitors. ChemMedChem, 3, 1323-1336.
158. Nguyen, J.T.,Hamada, Y., Kimura, T., and Kiso, Y. (2008) Design of potent aspartic protease inhibitors to treat various diseases. Archiv der Pharmazie, 341, 523-535.
159. Orrling, K.M.,Marzahn, M.R., Gutierrezde-Teran, H., Aqvist, J., Dunn, B.M., and Larhed, M. (2009) alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases. Bioorganic & Medicinal Chemistry, 17, 5933-5949.
160. Ramirez, A.R., Guerra, Y., Otero, A., Garcia, B., Berry, C., Mendiola, J., Hernandez-Zanui, A., and Chavez Mde, L. (2009) Generation of an affinity matrix useful in the purification of natural inhibitors of plasmepsin II, an antimalarial-drug target. Biotechnology and Applied Biochemistry, 52, 149-157.
161. Rumsh, L.D., Mikhailova, A.G., Mikhura, I.V., Prudchenko, I.A., Chikin, L.D., Mikhaleva, I.I., Kaliberda, E.N., Dergousova, N.I., Mel?nikov, E.E., and Formanovskii, A.A. (2008) [Selective inhibitors of plasmepsin II from Plasmodium falciparum based on pepstatin]. Bioorganicheskaia Khimiia, 34, 739-746.
162. Carroll, C.D.and Orlowski, M. (1998) Screening aspartyl proteases with combinatorial libraries. Advances in Experimental Medicine and Biology, 436, 375-380.
163. Flotow, H., Leong, C.Y., and Buss, A.D. (2002) Development of a plasmepsin II fluorescence polarization assay suitable for high throughput antimalarial drug discovery. Journal of Biomolecular Screening, 7, 367-371.
164. Ersmark, K., Samuelsson, B., and Hallberg, A. (2006) Plasmepsins as potential targets for new antimalarial therapy. Medicinal Research Reviews, 26, 626-666.
165. Skinner-Adams, T.S., McCarthy, J.S., Gardiner, D.L., Hilton, P.M., and Andrews, K.T. (2004) Antiretrovirals as antimalarial agents. The Journal of Infectious Diseases, 190, 1998-2000.
166. Mimoto, T., Hattori, N., Takaku, H., Kisanuki, S., Fukazawa, T., Terashima, K., Kato, R., Nojima, S., Misawa, S.,Ueno, T., Imai, J., Enomoto, H., Tanaka, S., Sakikawa, H., Shintani, M., Hayashi, H., and Kiso, Y. (2000) Structure-activity relationship of orally potent tripeptidebased HIV protease inhibitors containing hydroxymethylcarbonyl isostere. Chemical & Pharmaceutical Bulletin, 48, 1310-1326.
167. Kiso, Y. (1998) Design and synthesis of a covalently linked HIV-1 protease dimer analog and peptidomimetic inhibitors. Journal of Synthetic Organic Chemistry Japan, 56, 896-907.
168. Mimoto, T., Kato, R., Takaku, H., Nojima, S., Terashima, K., Misawa, S., Fukazawa, T., Ueno, T., Sato, H., Shintani, M., Kiso, Y., and Hayashi, H. (1999) Structure-activity relationship of smallsized HIV protease inhibitors containing allophenylnorstatine. Journal ofMedicinal Chemistry, 42, 1789-1802.
169. Silva, A.M., Lee, A.Y., Erickson, J.W., and Goldberg, D.E. (1998) Structural analysis of plasmepsin II. A comparison with human aspartic proteases. Advances in Experimental Medicine and Biology, 436, 363-373.
170. Holdgate, G.A. (2001)Making cool drugs hot: isothermal titration calorimetry as a tool to study binding energetics. Biotechniques, 31, 164-166. 168, 170 passim.
171. Brun, R.and Kunz, C. (1989) In vitro drug sensitivity test for Trypanosoma brucei subgroup bloodstream trypomastigotes. Acta Tropica, 46, 361-368.
172. Bailly, E., Jambou, R., Savel, J., and Jaureguiberry, G. (1992) Plasmodium falciparum: differential sensitivity in vitro to E-64 (cysteine protease inhibitor) and pepstatin A (aspartyl protease inhibitor). The Journal of Protozoology, 39, 593-599.
173. Peters, W., Portus, J.H., and Robinson, B.L. (1975) The chemotherapy of rodent malaria XXII. Annals of Tropical Medicine and Parasitology, 69, 155-171.
174. Thompson, J.D., Higgins, D.G., and Gibson, T.J. (1994) Clustal W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties, and weight matrix choice. Nucleic Acids Research, 22, 4673-4680.
175. Bhaumik, P., Xiao, H., Parr, C.L., Kiso, Y., Gustchina, A., Yada, R.Y., and Wlodawer, A. (2009) Crystal structures of the histoaspartic protease (HAP) from Plasmodium falciparum. Journal of Molecular Biology, 388, 520-540.